Article • Critically ill adults

CPOCTs in development

Waiting for test results can be a minor inconvenience for some patients, but for those who are critically ill, timing matters. At the CPOCT International Symposium in Copenhagen (21-24 September) Dr Craig Lilly, a professor of medicine at the University of Massachusetts spoke about the point-of-care testing market, outlining currently available testing for critically ill adults, and also under development.

Report: Lisa Chamoff

Photo
Craig M Lilly MD is Professor of Medicine at the University of Massachusetts Medical School in Worcester, Maryland

‘Knowing the test value will be impactful for patients’ experience and outcomes,’ Lilly said. ‘Sometimes it doesn’t matter if you know now or know within a few hours. There is some testing where knowing right now matters.’

Lilly discussed tests currently used in the USA, such as blood glucose testing, and the frequency of use, as well as tests that might be available in the future. He also spoke of the value proposition of future testing — specifically, which tests will make sense to develop further despite the high costs of development.

Some tests currently in development make sense for investment, the professor pointed out. Tests in development are centred on infectious diseases, and there are also tests routinely used for acute coronary symptoms, or for neurological emergencies, that are not currently available in the point-of-care format, but which are likely to be widely used in the future.

‘We currently don’t have tests for neurological emergencies and we really need them,’ Lilly said.

Many facilities are not equipped with easy ways to test for problems that require urgent action, and that’s where the value lies in developing point-of-care tests, he added. ‘If you are in nursing home and develop chest pain in middle of night, the nursing home can’t do an electrocardiogram and blood work. They put you in an ambulance. That is both inconvenient and expensive. If you can do tests at the point of care, within the skilled nursing facility, the avoided costs more than justify making the point of care test available.’

06.11.2016

More on the subject:
Read all latest stories

Related articles

Photo

News • Spit take

Portable diagnostic detects SARS-CoV-2 RNA and antibodies

The prototype device combines eRapid and SHERLOCK technologies into a single, postcard-sized system that can simultaneously detect the presence of both SARS-CoV-2 RNA and antibodies in a patient’s…

Photo

Sponsored • Handheld diagnostics

Veros™ COVID-19 test now available in Europe

Handheld, instrument-free test delivers lab-quality molecular results – 97.9% accuracy – in about 15 minutes, right at the point of care.

Photo

Article • Point-of-care testing

POCT: a “win-win” scenario for all involved

Point-of-care testing (POCT) is a “win-win” scenario for patients and healthcare professionals in delivering care when and where it is needed, according to pathologist Adil Khan, MSc, PhD.

Related products

KABE Labortechnik – Consumables for blood gas analysis

Blood Gases /Electrolytes /Oximetry

KABE Labortechnik – Consumables for blood gas analysis

KABE LABORTECHNIK GmbH
Mesalvo – LabCentre

LIS, Middleware, POCT

Mesalvo – LabCentre

Mesalvo Mannheim GmbH (ehemals i-SOLUTIONS Health GmbH)
Siemens Healthineers – RapidPoint 500e Blood Gas System

Blood Gases, Electrolytes, Oximetry

Siemens Healthineers – RapidPoint 500e Blood Gas System

Siemens Healthineers
Subscribe to Newsletter